Clario Strengthens Neuroscience Portfolio with NeuroRx Buyout
Clario, a prominent provider of endpoint data solutions within the clinical trial industry, has announced a strategic acquisition of NeuroRx, furthering its expertise in neuroscience.
Clario's chief executive officer, Chris Fikry, expressed enthusiasm about this important acquisition. He highlighted its significance in reinforcing Clario’s leadership in imaging and expanding capabilities crucial for advancing medical innovation. Fikry indicated that this union positions the company to better support clients in their quest to develop transformative therapies.
NeuroRx has gained recognition for its extensive array of imaging-related services tailored for clinical trials. These services range from providing protocol assistance to data interpretation and reporting. NeuroRx has notably been involved in supporting the approval processes for a variety of neurological therapies, contributing to the approval of twelve FDA-approved drugs for multiple sclerosis since 2011.
Douglas Arnold, M.D., the founder and CEO of NeuroRx, will assume the role of Senior Scientific Advisor at Clario. Arnold stated that his team is dedicated to advancing imaging sciences to foster revolutionary treatments for neurological disorders. Citing experience with over 300 clinical trials, he underscored the profound impact of advanced image analysis on drug development. Joining Clario will allow his team to amplify their influence and innovation in the field.
This acquisition is part of a broader growth strategy as Clario recently signed a definitive agreement to acquire WCG’s eCOA business. Collectively, these acquisitions are expected to bolster Clario’s scientific expertise and service delivery in neuroscience, which presents unique challenges in the medical landscape.
Joyce Suhy, Ph. D., who serves as Clario's executive vice president and general manager of Medical Imaging and Specialty Solutions, remarked on the complexities associated with neuroscience. She noted that effectively addressing these challenges necessitates deep expertise and a resolute commitment. With NeuroRx’s addition to Clario’s team, they gain crucial imaging capabilities that have significantly influenced multiple sclerosis drug development, as well as treatments for conditions such as Huntington's, Parkinson's, and Alzheimer’s diseases.
Clario has long been a key player in providing endpoint data solutions to the clinical trials sector, generating robust clinical evidence for life sciences companies. Their comprehensive suite of evidence-generation solutions includes medical imaging, eCOA, precision motion analysis, cardiac solutions, and respiratory endpoints.
For more than five decades, Clario has demonstrated unwavering dedication to enhancing health outcomes globally through its specialized scientific knowledge and broad technological capabilities. Over their operational history, Clario’s solutions have underpinned clinical trials across 26,000 instances in over 100 countries. The company’s global network of experts contributes to the endorsement of over 60% of all FDA drug approvals since 2012.
Clario is backed by controlling shareholders Astorg, Nordic Capital, Novo Holdings, and Cinven, affirming investor confidence in its operational strategies and objectives.
NeuroRx, established in 2002, excels in offering imaging solutions, particularly for diseases that impact the Central Nervous System (CNS). Their expertise extends to multiple sclerosis, Huntington's, Parkinson's, Alzheimer's, and other rare neurological conditions. The company has lent its expertise to clinical studies spanning 82 countries and has participated in over 300 trials, underscoring their global impact in the neuroscience realm.
Frequently Asked Questions
What is the significance of Clario's acquisition of NeuroRx?
The acquisition solidifies Clario's leadership in the neuroscience field by enhancing its imaging capabilities and service offerings in clinical trials.
Who is Douglas Arnold and what role will he play at Clario?
Douglas Arnold is the founder and former CEO of NeuroRx, and he will become the Senior Scientific Advisor at Clario, contributing his extensive knowledge in imaging science.
What other acquisition has Clario recently announced?
Alongside the NeuroRx acquisition, Clario has also signed an agreement to acquire WCG's eCOA business, further enhancing its service capabilities.
How long has Clario been in operation?
Clario has been providing endpoint data solutions for over 50 years, demonstrating a long-standing commitment to transforming lives through clinical trials.
What types of illnesses does NeuroRx specialize in?
NeuroRx specializes in imaging for various neurological diseases, including multiple sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer’s disease.
